FDA Hold On Cloretazine Phase III Trial Is Lifted, Putting Vion On Track For 2008 NDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Company concedes it could run out of cash in 2009 if cancer drug is not commercialized.
You may also be interested in...
Vion Submits Laromustine For Use In Niche Population
Vion takes the quickest path to market for laromustine, now Onrigin, by submitting an NDA for use in elderly patients with poor prognosis.
Vion Submits Laromustine For Use In Niche Population
Vion takes the quickest path to market for laromustine, now Onrigin, by submitting an NDA for use in elderly patients with poor prognosis.
Vion Suspends Cloretazine Phase III Enrollment In Leukemia Patients
Suspension is a “hiccup” but development of the alkylating agent for adult myelogenous leukemia will move forward, Vion CEO Kessman states.